{"nctId":"NCT01040780","briefTitle":"Safety and Efficacy Study of Icotinb in Non-small Cell Lung Cancer (NSCLC) Patients","startDateStruct":{"date":"2009-02"},"conditions":["Non-small Cell Lung Cancer"],"count":399,"armGroups":[{"label":"Icotinib","type":"EXPERIMENTAL","interventionNames":["Drug: Icotinib"]},{"label":"Gefitinib","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Gefitinib"]}],"interventions":[{"name":"Icotinib","otherNames":["BPI-2009","Conmana"]},{"name":"Gefitinib","otherNames":["ZD1839","Iressa"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Confirmed NSCLC with Histology or cytology; advanced ï¼ˆIIIb/IV).\n2. Must have received 1 or 2 chemotherapy (at least 1 is platin based)before, and prior chemotherapy must be completed at least 4 weeks before study enrollment; =.\n\nExclusion Criteria:\n\n1\\. Previous usage of EGFR-TKI or antibody to EGFR: gefitinib, erlotinib, herceptin, erbitux.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"75 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Progression Free Survival","description":"Progression is defined, using RECIST, as a measurable increase in the smallest dimension of any target or non-target lesion, or the appearance of new lesions, since baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.6","spread":null},{"groupId":"OG001","value":"3.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall Survival","description":"Median number of months from first study treatment until time of death","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13.3","spread":null},{"groupId":"OG001","value":"13.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Best Tumor Response","description":"Change in size of tumor: Complete Response (CR) = no measurable tumor; Partial Response (PR) = 30% decrease in size of measurable tumor; Stable Disease (SD) = measurable tumor size has not changed; Progressive Disease (PD) = measurable tumor larger than at baseline","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.5","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"27.1","spread":null},{"groupId":"OG001","value":"27.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"47.7","spread":null},{"groupId":"OG001","value":"47.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"21.1","spread":null},{"groupId":"OG001","value":"20.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"75.4","spread":null},{"groupId":"OG001","value":"74.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Time To Progression","description":"Median time until disease progression. Disease progression defined as radiological and/or symptomatic disease progression.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.2","spread":null},{"groupId":"OG001","value":"3.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Safety and Tolerability","description":"Adverse Events (AEs) and Serious AEs (SAEs) are presented regardless of causality for patients who received at least one dose of Icotinib or Gefitinib. Events were graded by the investigator using the NCI CTCAE Scale (version 3.0) which provides a grading scale for each AE term.\n\nGrade 3 = Severe Grade 4 = Life-threatening or disabling","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"166","spread":null},{"groupId":"OG001","value":"165","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"121","spread":null},{"groupId":"OG001","value":"140","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13","spread":null},{"groupId":"OG001","value":"15","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null},{"groupId":"OG001","value":"10","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":13,"n":200},"commonTop":["Rash","Diarrhea","Pain","Aminotransferase Increased","Cough"]}}}